ClinicalTrials.gg
RecruitingNCT07430488RELIEFUpdated Nov 12, 2026

Effect of Reading a Personal Narrative Book on Emotional Regulation in Women of Childbearing Age Undergoing Hysterectomy (RELIEF)

An interventional study of personal narrative book in Hysterectomy, Anxiety and Depression, sponsored by Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI). Recruiting at 4 sites in France. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Depression with a site in France — 63 open to participants now, 67 under way, 2 of them phase 3. Depression · France.

Planned enrollment
74th of 185
156 · median 120
Started
2026
with 16 others
No phase
133 of 266
43 open now
Primary completion
2028-01
later than 46 of 66 live
Registered
254th of 266
by date

Among the 266 studies in Depression with a site in France, this one is the 74th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2026, is one of 133 with no phase, reaches primary completion later than 46 of the 66 other live ones, and was the 254th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

63 of the 266 studies in Depression with a site in France are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Depression with a site in France, or all of them as a file.
02

Study summary

The goal of this interventional clinical trial involving minimal risks and constraints is to evaluate whether an innovative approach to managing catastrophizing in the preoperative context of hysterectomy improves psychological outcomes compared to usual care in women of childbearing age who have been informed of an indication for hysterectomy.

The main questions it aims to answer are:

  • Does the use of a personal narrative book improve adaptive emotional regulation and reduce catastrophizing, anxiety, and depressive symptoms in the preoperative period?
  • Does this intervention improve postoperative patient satisfaction and reduce the need for additional supportive measures?

Researchers will compare standard care (CNGOF information leaflet with psychological consultation if needed) with an intervention including a personal narrative book in addition to standard care, to see if the intervention improves emotional regulation, psychological well-being, and satisfaction.

Participants will:

  • provide explicit oral informed consent;
  • complete questionnaires on their emotional and psychological experience;
  • read a personal narrative book if they are randomized to the intervention group.
03

Conditions studied

  • Hysterectomy
  • Anxiety
  • Depression
  • Catastrophizing

Browse trials for

04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 156 is above the median of 81 across 7,089 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

This is the only study on the registry with Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI) as lead sponsor.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older and under 43 years of age
  • Patients with an indication for hysterectomy for a non-malignant condition
  • Patients who have provided explicit oral consent to participate
  • Patients covered by the French social security system
  • Patients able to read and understand French and capable of reading a French book within a timeframe compatible with the study schedule

Exclusion criteria

Exclusion Criteria:

  • Women with suspected uterine cancer or high-grade dysplasia
  • Women participating or having participated to an interventional clinical trial within the 30 days prior to inclusion
  • Pregnant, breastfeeding, or parturient women
  • Protected patient: adults under guardianship or other legal protection; persons deprived of liberty by judicial or administrative order; persons hospitalized without consent
  • Patients with insufficient proficiency in the French language
06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • No intervention
    Standard care

    CNGOF information leaflet with a consultation with a psychologist or other additional supportive measures if needed.

  • Experimental
    Intervention ("Personal Narrative" arm)

    CNGOF information leaflet, personal narrative book, and a consultation with a psychologist or other additional supportive measures if needed.

    Other: personal narrative book

Interventions

  • Otherpersonal narrative book

    Reading a personal narrative book written by a patient who underwent a hysterectomy

07

What researchers measure

Primary outcomes

  1. Adaptive regulation

    The adaptative regulation is measured using the Cognitive Emotion Regulation Questionnaire - Adaptive (CERQ-A) wich include five adaptive subscales . Scores range from 20 to 100, with higher scores indicating better adaptive regulation.

    Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.

Secondary outcomes

  1. Anxiety and depression

    The outcome is measured using the Hospital Anxiety and Depression Scale (HADS). The scale includes two subscales: Anxiety (HADS-A) and Depression (HADS-D). Each subscale ranges from 0 to 21, with higher scores indicating more severe symptoms.

    Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.

  2. Adaptive and maladaptive regulation

    This outcomes is measured using the Cognitive Emotion Regulation Questionnaire (CERQ). Two composite scores are derived: adaptive regulation and maladaptive regulation. The adaptative regulation is measured using the Cognitive Emotion Regulation Questionnaire - Adaptive (CERQ-A) wich include five adaptive subscales . Scores range from 20 to 100, with higher scores indicating better adaptive regulation. The maldaptative regulation is measured using the Cognitive Emotion Regulation Questionnaire - Non-Adaptive (CERQ-NA) wich include four maladaptive subscales. Scores range from 16 to 80, with higher scores indicating greater use of maladaptive regulation strategies.

    Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.

  3. Catastrophizing

    The outcome is measured using the Symptom Catastrophizing Scale (SCS), a 7-item questionnaire assessing catastrophic thinking related to symptoms. Total scores range from 0 to 14.

    Time frame: between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.

  4. Use of additional supportive measures

    The questionnaire is completed by the physician based on the prescription made or recommended to the patient. The questions are independent and do not generate a score.

    Time frame: at the inclusion (D0)

  5. Use of additional supportive measures

    The questionnaire is completed by the patient. The questions are independent and do not generate a score.

    Time frame: Postoperative, occuring 1 to 3 months after inclusion.

  6. Patient satisfaction

    The outcome is measured using the Likert-type satisfaction scale to determine satisfaction with their care. Responses range from "extremely satisfied" to "extremely dissatisfied."

    Time frame: Postoperative, occuring 1 to 3 months after inclusion.

08

Study locations

4 of 4 sites recruiting
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Feb 24, 2026
StartActual
May 13, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07430488
Lead sponsor
Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI)
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
May 13, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion